checkAd

Xoma 200-Prozent-Chance !!!! ????? !!!!! - 500 Beiträge pro Seite (Seite 34)

eröffnet am 17.08.03 12:35:15 von
neuester Beitrag 18.04.17 18:55:14 von

ISIN: US98419J2069 | WKN: A2ATUH | Symbol: XOMA
22,320
$
15.01.22
Nasdaq
+1,45 %
+0,320 USD

  • 1
  • 34

Begriffe und/oder Benutzer

 

Fragen

 Ja Nein
Avatar
29.06.16 22:24:24
Beitrag Nr. 16.501 ()
Avatar
29.06.16 22:28:26
Beitrag Nr. 16.502 ()
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
06.09.16 20:39:07
Beitrag Nr. 16.503 ()
Antwort auf Beitrag Nr.: 52.726.618 von gerdass am 29.06.16 22:28:26was ist denn da heute los
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
06.09.16 20:42:38
Beitrag Nr. 16.504 ()
Antwort auf Beitrag Nr.: 53.220.504 von kunokuhn am 06.09.16 20:39:07XOMA hat gezündet:D
Avatar
06.09.16 22:31:25
Beitrag Nr. 16.505 ()
Gezündet wegen nem Hüpfer von 4 !!!! CENT? Was sagst dann zu MSTX??

Nee, Nee, wenns keine Eintagsfliege wird sollte mich das schwer wundern.

Tommi
Avatar
18.10.16 17:27:12
Beitrag Nr. 16.506 ()
wurde die Gesplittet ?
3 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
18.10.16 18:31:51
Beitrag Nr. 16.507 ()
Antwort auf Beitrag Nr.: 53.500.791 von kunokuhn am 18.10.16 17:27:12XOMA Announces Reverse Stock Split

BERKELEY, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that, at a special meeting of the Company's stockholders held on October 14, 2016, its stockholders voted to approve a reverse stock split of the Company's issued and outstanding common stock. XOMA's Board of Directors then determined that the split would be at a ratio of 1-for-20. Upon the effectiveness of the reverse stock split, every 20 shares of XOMA common stock will be converted into 1 share of common stock. No fractional shares will be issued in connection with the reverse stock split. A stockholder who otherwise would have been entitled to receive a fractional share of stock as a result of the reverse stock split will instead receive cash in lieu of fractional shares.

The reverse stock split is intended to enable XOMA to regain compliance with the $1.00 minimum bid price required for continued listing on the NASDAQ Global Market and help increase shareholder interest in our stock.

The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of XOMA's shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares).

Well Fargo Shareowner Services, XOMA's transfer agent, will provide instructions to stockholders regarding the process for exchanging their shares and stock certificates. Additional information regarding the reverse stock split approved by stockholders can be found in XOMA's definitive proxy statement filed with the Securities and Exchange Commission on September 12, 2016.

The Company expects the reverse stock split to become effective at 5:00 p.m. EDT on Monday, October 17, 2016. When the market opens on Tuesday, October 18, 2016, XOMA's common stock will begin trading on the NASDAQ Global Market on a split-adjusted basis.

http://investors.xoma.com/releasedetail.cfm?ReleaseID=993692
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
18.10.16 19:02:48
Beitrag Nr. 16.508 ()
Antwort auf Beitrag Nr.: 53.501.367 von Tommi33 am 18.10.16 18:31:51Das würde bedeuten, dass Xoma bei ~ 7,00 $ notiert und dass hier relativ nahe eine Nachricht kommt.
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
18.10.16 19:30:21
Beitrag Nr. 16.509 ()
Antwort auf Beitrag Nr.: 53.501.646 von specku am 18.10.16 19:02:48Im Moment eher bei 6$, und ausser das sie erfolgreich re-gesplittet haben wird m.M.n. nix kommen.
Warum auch, Geld verbrennen geht weiter, ich hoffe ja mal nicht das sie noch ne KE hinterher schieben.

Tommi
Avatar
19.10.16 16:40:14
Beitrag Nr. 16.510 ()
Kam jetzt doch anders wie gedacht, aber ob das jetzt der Bringer ist sollte jeder selbst entscheiden:

XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism

Company Reached Agreement with MHRA on General Trial Design for Multi-dose Testing in Children 2 Years and Older in the United Kingdom

BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company's proposal to initiate a multi-dose Phase 2 clinical study of XOMA 358 in children two years and older diagnosed with Congenital Hyperinsulinism (CHI).

"MHRA officials clearly recognize the importance and complexity of conducting a clinical program in CHI, an orphan disease that affects children and infants for whom few effective treatment options are available. The comments resulting from our national advice meeting with the MHRA officials, regarding its requirements to support expedited clinical development for XOMA 358, were clear and thorough," commented Paul Rubin, MD, Senior Vice President Research and Development and Chief Medical Officer of XOMA. "Upon their formal review and acceptance of our protocol, XOMA will be able to launch its first multi-dose extended treatment clinical study for XOMA 358 in CHI patients over the age of two."

"Today's announcement reflects the priority we have placed on our regulatory efforts. Opening our clinical program to younger patients and offering multi-dose studies is a critical step to accelerate XOMA 358 development and reach the patients we believe are most likely to benefit from this first-in-class monoclonal antibody. Additionally, the regulatory body in Germany recently approved our plan to conduct a repeat-dose clinical study in CHI patients over the age of 12. Our first German site has begun enrolling patients and has already contributed to a substantial acceleration in enrollment in our XOMA 358 studies," stated John Varian, Chief Executive Officer of XOMA. "We look forward to continuing our conversations with the MHRA, the European Medicines Agency (EMA), and the US Food & Drug Administration (FDA) to advance the development of XOMA 358, enabling us to get this important treatment to children in need as expeditiously as possible."
http://investors.xoma.com/releasedetail.cfm?releaseid=994356" target="_blank" rel="nofollow ugc noopener">
http://investors.xoma.com/releasedetail.cfm?releaseid=994356
Avatar
19.10.16 16:49:23
Beitrag Nr. 16.511 ()
Das erinnert mich doch hier sehr an aezs. Dort ging der Kurs nach dem RS auch um 20-30% runter, ehe er dann um knapp 500% up ging. Ich beobachte das hier mal...:cool:
4 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
19.10.16 17:19:09
Beitrag Nr. 16.512 ()
Antwort auf Beitrag Nr.: 53.509.308 von strongbuyamitelo am 19.10.16 16:49:23Den gedanken hatte ich ja auch. Insbesondere nach der letzten Nachricht müsste es hier spätestens nächste woche hoch gehen. 500% ist eher unrealistisch. Aber 100-200% müssten hier bis jahresende allemal werden. Bleibe auf der pirsch und das jeden tag...
Avatar
19.10.16 17:31:00
Beitrag Nr. 16.513 ()
Antwort auf Beitrag Nr.: 53.509.308 von strongbuyamitelo am 19.10.16 16:49:23500% ?? Zeig mir bitte wann das gewesen sein soll, das muss an mir vorbeigegangen sein und ich glaube meine Brille ist auch defekt weil im Chart sehe ich auch keine 500% UP









Einfaches Einfügen von wallstreet:online Charts: So funktionierts.


Tommi
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
19.10.16 18:19:17
Beitrag Nr. 16.514 ()
Antwort auf Beitrag Nr.: 53.509.716 von Tommi33 am 19.10.16 17:31:00Im Chart sieht man es auch nicht. Ging nach dem RS auf etwa 3,5 USD runter und dann auf 15 - 16 USD hoch.
Vielleicht waren es auch "nur" 400%.;)
Avatar
19.10.16 18:21:32
Beitrag Nr. 16.515 ()
Antwort auf Beitrag Nr.: 53.509.716 von Tommi33 am 19.10.16 17:31:00Nimm mal die "Kerzenversion" und gib als Zeitraum 1 Jahr ein. Dann siehst du es ganz gut.
Avatar
19.10.16 18:33:41
Beitrag Nr. 16.516 ()
Der eine Tag mit Eröffnung bei 4,78 und Höchstkurs 15,70? Also wer da unten zugegriffen und beim Hoch verkauft hat sollte Lotto spielen, soviel Glück kann man doch nur einmal haben.

Aber nun gut, ich hab mit Xoma schon soviel Scheisse erlebt, da glaubt man irgend wann nicht mehr an das Gute, aber ich lass mich gern vom Gegenteil überzeugen und dann schlägt die Gier wieder zu und schon ist man wieder der gearschte, thats life.

Tommi
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Avatar
19.10.16 18:54:39
Beitrag Nr. 16.517 ()
Antwort auf Beitrag Nr.: 53.510.190 von Tommi33 am 19.10.16 18:33:41Ging aber erst bis tief in die 3 USD runter. Weiß nicht mehr genau, bis wohin und dann kam der Rebound. Aber ja, sehr kurzfristig hielt das an. Aber hier entwickelt es sich vielleicht ähnlich.
Avatar
22.12.16 17:45:36
Beitrag Nr. 16.518 ()
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update

Up to $22 million in revenue generated through sale of royalty streams from two license agreements to HealthCare Royalty Partners, with an initial $18 million payment and up to $4 million in future milestones
Non-dilutive funding to support clinical advancement of XOMA 358 in a streamlined manner
Operational transformation eliminates 57 positions
Significantly reduced operating expense structure going forward
Jim Neal named Chief Executive Officer and joins the Board of Directors, replacing John Varian who retires but remains a member of the Board of Directors

BERKELEY, Calif., Dec. 21, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced several corporate actions to further streamline its operations to focus on XOMA 358 clinical development, monetize non-core assets, and strengthen its balance sheet.

“With this transaction, we have generated $83 million in non-dilutive liquidity since October 2015,” said Jim Neal, newly appointed Chief Executive Officer and Director of XOMA. “HealthCare Royalty Partners (“HCR”) has an established history of supporting the biotechnology industry. They provide companies with the opportunity to realize value in non-core assets without diluting equity shareholders. Two royalty agreements from XOMA’s extensive portfolio of licensed assets particularly attracted HCR’s interest. XOMA’s scientific discoveries have served us well, financing our clinical development over the past two years.”

Paul Hadden, Managing Director, HealthCare Royalty Partners, said, “We are extremely pleased to partner with XOMA on this asset sale, providing non-dilutive capital at an important point in their evolution.”

Tom Burns, Vice President, Finance, and Chief Financial Officer of XOMA, commented, “To further reduce our operating costs, we have taken two actions. First, we are using a portion of the proceeds from this transaction to partially repay our debt held by Hercules Technology Growth Capital, Inc. (“Hercules”). Second, to reflect our operational focus on advancing XOMA 358, we are streamlining our team and eliminating 57 positions. These two actions will significantly reduce our expenses so the company can more efficiently fund XOMA 358 clinical development.”

John Varian stated, “I believe XOMA is well positioned, and this is the right time for me to retire and turn the reins over to Jim Neal. He has the right plan in place to ensure the company achieves its next clinical development and financial goals.”

Denny Van Ness, XOMA’s Chairman of the Board, stated, “As Chief Operating Officer, Jim has been leading the XOMA 358 project team, as well as leading the company’s business development activities. The Board, John, and I have every confidence that Jim and his team will take XOMA 358 forward in a cost-effective manner and continue to drive the licensing of XOMA’s non-core assets.”

“XOMA 358 is an important potential therapy for the patients and families affected by Congenital Hyperinsulinism (“CHI”) or who experience hypoglycemia post bariatric surgery. We now have over 25 patients enrolled in our two Phase 2 Proof-of-Concept studies, which reflects the desire for new therapeutic options in these rare indications. We need to do everything possible to develop XOMA 358 and bring it to market,” Mr. Neal added. “The financing and the operational cost reductions we announced today allow us to aggressively move forward. Our next step is launching our multi-dose study in CHI patients. Importantly, we have retained other non-core assets that could potentially be deployed in the future to fund our clinical development efforts.”

HealthCare Royalty Partners Asset Sale

XOMA sold its rights under two license agreements to its patented bacterial cell expression technology. The first of these covers TRUMENBA®, a meningococcal group B vaccine marketed by Pfizer, on which XOMA has been receiving low single-digit royalties from commercial sales. The second agreement is with Dyax Corp. All rights to future royalties and other payments associated with these licenses have been acquired by HCR as detailed in the Form 8-K filed on December 21, 2016.

Hercules Technology Growth Capital, Inc.

XOMA entered into a Loan and Security Agreement with Hercules in 2015 under which XOMA borrowed $20.0 million. The company has been paying principal and accrued interest since July 1, 2016, and the loan is scheduled to mature on September 1, 2018. On September 30, 2016, the outstanding balance was $18.5 million. In January, XOMA will apply $10 million from the HCR asset sale proceeds to reduce its debt obligation to Hercules.

Corporate Restructuring

Based upon the data being generated in the XOMA 358 clinical studies in patients with hypoglycemia due to Congenital Hyperinsulinism or post bariatric surgery, XOMA is preparing to expand the program into multi-dose clinical studies. These two indications are rare conditions with very high unmet therapeutic needs. Therefore, the company is concentrating its investments on clinical development, with an initial focus on the XOMA 358 clinical programs.

To reflect this narrowed corporate focus, the company will reduce its headcount by 57 positions.

“We have shown the assets that XOMA has discovered and developed hold significant interest to companies dedicated to improving human health. Importantly, we retain the future revenue streams from our most recent licensing agreements with Novartis and NovoNordisk,” commented Mr. Burns. “We continue to expect we will earn a $10 million milestone payment within the next few months under one of our existing license or collaboration agreements. In light of the interest we have received from our recently unveiled IL-2 antibody program for immuno-oncology and our PTH1R program for oncology indications, we believe these two assets could provide additional funding to support our development plans for XOMA 358 in CHI and post-bariatric surgery.”

About XOMA Corporation

XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company has ongoing Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism, and in patients with hypoglycemia after bariatric surgery. For more information, visit www.xoma.com.

About HealthCare Royalty Partners

HealthCare Royalty Partners (HCR) is a private investment firm that purchases royalties and, using debt-like structures, invests in commercial or near-commercial stage assets for life science companies. HCR has raised approximately $3.4 billion in committed capital and is headquartered in Stamford, CT. Over the past decade, HCR's senior professionals have completed more than 60 healthcare investments. For more information, visit www.healthcareroyalty.com.

Forward-Looking Statements

Certain statements contained in this press release including statements related to reaching future payment milestones, the development and potential commercialization of XOMA 358, the impact of XOMA’s elimination of employee positions and planned repayment of Hercules debt, the transition in XOMA’s leadership, the expected sources of future revenues, and other statements that relate to future periods are each forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail under the heading “Risk Factors” contained in XOMA’s quarterly report on Form 10-Q for the quarter ended September 30, 2016, which is on file with the Securities and Exchange Commission, and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by law.

http://investors.xoma.com/releasedetail.cfm?ReleaseID=100527…
Avatar
18.04.17 18:55:14
Beitrag Nr. 16.519 ()
Neue WKN - Neuer Thread
Hier gehts weiter mit neuer WKN -> http://www.wallstreet-online.de/diskussion/1250962-1-10/xom…
  • 1
  • 34
 Durchsuchen


Beitrag zu dieser Diskussion schreiben


Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
hier
eine neue Diskussion.
Xoma 200-Prozent-Chance !!!! ????? !!!!!